Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
• Useful for cell-based GCGR binding assay
• Screen for human GCGR agonists based on cAMP accumulation assay
Expression analysis of human GCGR on HEK293/Human GCGR Stable Cell Line by FACS.
Cell surface staining using Alexa 488-labeled anti-human GCGR antibody was performed on HEK293/Human GCGR Stable Cell Line with different expression levels: HEK293/Human GCGR Stable Cell Line (Low Expression); HEK293/Human GCGR Stable Cell Line (Medium Expression); HEK293/Human GCGR Stable Cell Line (High Expression).
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Hypoglycemia | Details | |||||
Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | Japan | Hypoglycemia | Novo Nordisk A/S | 1998-06-22 | Diabetes Mellitus, Type 1; Hypoglycemia; Obesity | Details |
Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals Inc | Gvoke | United States | Hypoglycemia | Xeris Pharmaceuticals Inc | 1960-01-01 | Hypoglycemia; Hyperinsulinism | Details | |
Glucagon (rDNA origin, Lilly) | Approved | Eli Lilly And Company | Glucagon | United States | Hypoglycemia | Eli Lilly And Company | 1998-09-11 | Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity | Details | |
Glucagon | MP-123456B | Approved | Eli Lilly And Company | Baqsimi, Ogluo | EU | Hypoglycemia | Eli Lilly Nederland BV | 1960-11-14 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | Zegalogue | United States | Hypoglycemia | Zealand Pharma Us Inc | 2021-03-22 | Congenital Hyperinsulinism; Diabetes Mellitus, Type 1; Hypoglycemia; Hyperinsulinism; Glucose Metabolism Disorders | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
Human glucagon(Shanghai Duomirui) | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Hypoglycemia | Details | |
ISIS-325568 | ISIS-325568 | Ionis Pharmaceuticals Inc | Details | ||
MK-3577 | MK-3577 | Merck Sharp & Dohme Corp | Details | ||
IONIS-GCGRRx | IONIS-GCGRRx; ISIS-449884; ISISGCGRRx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
Bamadutide | SAR-425899 | Sanofi | Details | ||
MK-0893 | MK-0893; L-001241689 | Merck & Co Inc | Details | ||
PF-06291874 | PF-6291874; PF-06291874 | Pfizer Inc | Details | ||
MK-5823 | MK-5823 | Merck Sharp & Dohme Corp | Details | ||
MK-8521 | MK-8521 | Merck Sharp & Dohme Corp | Details | ||
LGD-6972 | LGD-6972; MB-11262; RVT-1502 | Ligand Pharmaceuticals Inc | Details | ||
Glucagon biosimilar (Hospira) | Hospira | Details | |||
BioChaperone Glucagon | BC Glucagon | Adocia | Details | ||
Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences Inc | Diabetes Mellitus, Type 2; Obesity | Details | |
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
BI-456906 | BI-456906 | Phase 2 Clinical | Zealand Pharma A/S | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Liver Cirrhosis; Liver Diseases; Obesity; Overweight | Details |
DR-10624 | DR-10624 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Diabetes Mellitus | Details |
Pemvidutide | ALT-801(Altimmune); SP-1373; VPD-107 | Phase 2 Clinical | Velocity Pharmaceutical Development | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
RBD-4988 | RBD-4988 | Phase 2 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Diabetes Mellitus, Type 2 | Details |
Efinopegdutide | JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic | Details |
HM-15136 | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 | Details |
volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus | Details |
TB-001 | TB001; TB-001 | Phase 1 Clinical | Shenzhen Tuwei Anchuang Technology Development Co Ltd | Non-alcoholic Fatty Liver Disease; Liver Cirrhosis | Details |
Cotadutide | MEDI-0382 | Phase 3 Clinical | Medimmune Llc | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Obesity; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
Mazdutide | OXM-3; IBI-362; LY-3305677 | Phase 3 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
retatrutide | LY-3437943 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Renal Insufficiency; Obesity; Overweight | Details |
DD-01 | DD-01 | Phase 1 Clinical | Neuraly Inc, D&D Pharmatech | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
PB-718 | PB-718 | Phase 1 Clinical | Peg Bio Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
This web search service is supported by Google Inc.